Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market. The company announced the completion of two ...

Novo Nordisk has had a setback in its quest to develop an insulin pill, CEO Lars Rebien Sorensen has revealed, saying the drug would be too expensive for payers to stomach in its current form.